United-Guardian, Inc. (UG) AI Stock Analysis

United-Guardian, Inc. manufactures and markets cosmetic ingredients, pharmaceuticals, medical lubricants, and specialty industrial products globally. Headquartered in Hauppauge, New York, the company produces the LUBRAJEL line of water-based moisturizing and lubricating gels, as well as formulations such as LUBRAJEL NATURAL, LUBRAJEL MARINE, and LUBRASIL II SB. In healthcare, it provides medical lubricants including LUBRAJEL RR, RC, MG, LC, and FA for catheters, medical devices, and oral care. Its pharmaceutical portfolio includes RENACIDIN for catheter calcifications and antimicrobial agent CLORPACTIN WCS-90. Additionally, it offers industrial solutions including DESELEX and THOROCLENS, distributing products worldwide via marketing partners and wholesalers.

United-Guardian recorded annual revenue fluctuations between FY2021 and FY2025, dropping from $13.9M in FY2021 to $10.5M in FY2025, reflecting a 5-year revenue CAGR of -0.8%. In FY2025, revenue fell 13.4%, operating margin compressed to 21.3% from 29.9% in FY2024, and net income declined to $2.1M with EPS of $0.46. Over the trailing twelve months, revenue reached $11.2M with a profit margin of 22.0% and EPS of $0.54. In the latest quarter ended June 30, 2026, performance improved, with quarterly revenue growth of 9.5% year-over-year and quarterly earnings growth of 16.2% year-over-year.

As of June 30, 2026, United-Guardian held $8.9M in cash and short-term investments against total assets of $13.6M and shareholders' equity of $11.6M. Its liquidity profile is highlighted by a current ratio of 7.31. In FY2025, the company generated $2.0M in operating cash flow and $1.9M in free cash flow, with capital expenditures of $58,999. Capital returns focused on dividends, with $2.8M paid in FY2025, while the 5-year share count change was 0.0%.

United-Guardian trades at a trailing P/E of 12.7x and an EV/EBITDA of 9.7x, both below the median of its US-listed Consumer Defensive peers at 18.6x and 11.7x, respectively. However, its forward P/E of 26.5x and price-to-sales of 2.8x trade at a premium to peer medians of 14.3x and 0.7x. The company holds a market cap of $31.4M and an enterprise value of $23.7M. Over the past year, the stock returned -4.1% compared to a 16.8% return for the S&P 500 (SPY), while its 5-year return of -36.2% trailed SPY's 83.0% return.

United-Guardian pays a semiannual dividend with an annual forward payout of $0.60, representing a dividend yield of 8.77%. The company has paid dividends for 31 consecutive years. However, its payout ratio stands at 101.6%, and its 5-year annualized dividend growth is -5.1%. The last ex-dividend date was July 28, 2026.

United-Guardian does not have published analyst consensus ratings, price targets, or earnings estimates. The company's next scheduled earnings date is November 5, 2026. Institutional investors hold 20.4% of shares, while insider ownership accounts for 35.9%. Short interest remains low, with short interest representing 0.4% of the float.

This page is an AI-written research summary of United-Guardian, Inc. (UG). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: UG income statement, UG balance sheet, UG key metrics, UG chart. See the UG stock overview for the latest quote and news.